Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood

Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood

Highlights•Vaccines containing one of 3 AS families have been licensed since 2005. •Safety of each AS-antigen combination is evaluated individually. •New methods were developed to enhance safety assessment of vaccines containing AS. •Insights into mode of action are contributing to understanding vac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2019-09, Vol.37 (38), p.5670-5680
Hauptverfasser: Laupèze, Béatrice, Hervé, Caroline, Di Pasquale, Alberta, Tavares Da Silva, Fernanda
Format: Artikel
Sprache:eng
Schlagworte:
Adjuvant
Adjuvant System
Adjuvants
Allergy and Immunology
Aluminum
Antigens
AS01
AS03
AS04
Autoimmune diseases
Children
Clinical trials
Congenital diseases
Data collection
Girls
Hemodialysis
Hepatitis B
Herpes zoster
Human papillomavirus
Immune response
Immune system
Immunization
Immunostimulants
Infants
Infectious diseases
Influenza
Licenses
Malaria
Meta-analysis
Miscarriage
Mode of action
New technology
Pandemics
Parasitic diseases
Populations
Public health
Renal function
Safety
Stimulants
Vaccine
Vaccine development
Vaccines
Vector-borne diseases
Viral infections
Womens health
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights•Vaccines containing one of 3 AS families have been licensed since 2005. •Safety of each AS-antigen combination is evaluated individually. •New methods were developed to enhance safety assessment of vaccines containing AS. •Insights into mode of action are contributing to understanding vaccine safety. •Methods developed have progressed how we understand/investigate vaccine safety.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2019.07.098